Real-world evidence from the INSIGHTS-ILD registry: Impact of INBUILD criteria on disease progression and therapy modifications

Résumé fourni par la source

INSIGHTS-ILD (DRKS00027389) is a prospective registry at 35 German expert centers providing real-world insights into fibrosing interstitial lung disease (fILD). Inclusion criteria include interstitial lung fibrosis >10% on HRCT, DLCO ≤80% predicted, and active anti-inflammatory and/or antifibrotic therapy. To date, 826 patients were included. At baseline, 408 (49.4%) received anti-inflammatory therapy, 158 (19.1%) antifibrotic therapy, and 260 (31.5%) both. During follow-up, 60 (14.7%) initially on anti-inflammatory therapy modified treatment, with 56 transitioning to combination therapy. Among antifibrotic patients, 21 (13.3%) changed therapy, mostly (18 patients) to combination therapy. In the combination group, 41 (15.8%) changed therapy, with 28 stopping antifibrotic treatment. Data on INBUILD criteria for the 24 months prior to registry inclusion were available for 682 patients. Time-to-event analysis showed a significant difference in time to first therapy change or death between patients with at least one INBUILD criterion at baseline and those without (p<0.0001). However, no significant difference was observed in time to therapy modification or death when stratified by baseline therapy (anti-inflammatory, antifibrotic, or combination). In conclusion, INBUILD criteria at baseline predict disease progression within 12 months and are linked to a higher rate of therapy change. erj;66/suppl_69/PA2994/F1 F1 F1

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.